Yestar Healthcare Holdings Co Ltd (HK:2393)
:2393
Want to see HK:2393 full AI Analyst Report?
Top Page
Yestar Healthcare Holdings Co Ltd
(2393)
Select Model
Select Model
Rating:49Neutral
Price Target:
HK$0.07
▼(-31.00% Downside)
Action:Reiterated
Date:05/21/26
The score is held back primarily by deteriorating revenue and unstable profitability (despite strong 2025 cash flow and an improved balance sheet). Technicals further pressure the rating as the stock is in a clear downtrend with bearish momentum. Valuation is also difficult to support given negative earnings and no stated dividend yield.
Positive Factors
Improved balance sheet
The shift to positive equity and materially lower debt improves financial flexibility and reduces refinancing risk. Durable balance-sheet repair supports capacity for investment or downturns, making the company more resilient over the next several quarters.
Negative Factors
Sharp revenue contraction
A ~25% revenue decline in 2025 following flat/weak 2024 signals deteriorating demand or market share loss. Sustained top-line weakness undermines scale economics, stresses fixed-cost absorption, and constrains durable margin and earnings recovery prospects.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved balance sheet
The shift to positive equity and materially lower debt improves financial flexibility and reduces refinancing risk. Durable balance-sheet repair supports capacity for investment or downturns, making the company more resilient over the next several quarters.
Read all positive factors
Yestar Healthcare Holdings Co Ltd (2393) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$160.74M
Dividend YieldN/A
Average Volume (3M)2.34M
Price to Earnings (P/E)―
Beta (1Y)0.48
Revenue Growth-38.20%
EPS Growth-108.24%
CountryHK
Employees627
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.03
Shares Outstanding2,331,590,000
10 Day Avg. Volume1,184,000
30 Day Avg. Volume2,342,546
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.56
Price to Sales (P/S)0.14
P/FCF Ratio0.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Yestar Healthcare Holdings Co Ltd Business Overview & Revenue Model
Company Description
Yestar Healthcare Holdings Company Limited, an investment holding company, engages in the manufacture, distribution, and sale of medical imaging products in Mainland China. It operates through two segments, Imaging Printing Products, and Medical P...
How the Company Makes Money
null...
Yestar Healthcare Holdings Co Ltd Financial Statement Overview
Summary
Income Statement
41
Neutral
Balance Sheet
58
Neutral
Cash Flow
72
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.49B | 2.41B | 2.91B | 2.80B | 4.93B |
| Gross Profit | 266.86M | 399.20M | 512.78M | 397.55M | 848.70M |
| EBITDA | 37.64M | -51.93M | 376.81M | 19.13M | 315.89M |
| Net Income | -75.03M | 921.61M | -13.89M | -992.23M | 3.33M |
Balance Sheet | |||||
| Total Assets | 1.19B | 1.43B | 3.43B | 3.37B | 4.56B |
| Cash, Cash Equivalents and Short-Term Investments | 256.26M | 151.78M | 251.56M | 418.15M | 751.77M |
| Total Debt | 211.05M | 316.90M | 1.63B | 1.90B | 1.79B |
| Total Liabilities | 780.27M | 921.84M | 3.82B | 3.71B | 3.73B |
| Stockholders Equity | 378.26M | 461.60M | -457.50M | -408.87M | 755.23M |
Cash Flow | |||||
| Free Cash Flow | 289.40M | -26.45M | 294.22M | -115.58M | 665.55M |
| Operating Cash Flow | 311.31M | 12.72M | 387.67M | -91.73M | 715.22M |
| Investing Cash Flow | -16.97M | 380.42M | -89.82M | -18.72M | -47.67M |
| Financing Cash Flow | -153.52M | -502.63M | -234.37M | -180.86M | -654.20M |
Yestar Healthcare Holdings Co Ltd Technical Analysis
Negative
0.10
Price Trends
0.09
Negative
0.10
Negative
0.12
Negative
Market Momentum
>-0.01
Positive
25.35
Positive
22.01
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2393, the sentiment is Negative. The current price of 0.1 is above the 20-day moving average (MA) of 0.08, above the 50-day MA of 0.09, and below the 200-day MA of 0.12, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 25.35 is Positive, neither overbought nor oversold. The STOCH value of 22.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2393.
Yestar Healthcare Holdings Co Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | HK$553.90M | 5.13 | 16.21% | 4.94% | 16.46% | 50.51% | |
61 Neutral | HK$1.31B | 5.03 | 4.02% | 2.82% | 4.57% | -24.35% | |
57 Neutral | HK$415.19M | 11.85 | 4.12% | ― | 2.17% | 109.41% | |
56 Neutral | HK$5.69B | 9.87 | 6.19% | 2.76% | -4.92% | -19.51% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$160.74M | -2.82 | -17.70% | ― | -38.20% | -108.24% | |
42 Neutral | HK$426.70M | -2.05 | -17.38% | ― | -21.90% | 5.78% |
* Healthcare Sector Average
HK:2393
Yestar Healthcare Holdings Co Ltd
0.07
-0.03
-31.00%
HK:1612
Vincent Medical Holdings Limited
0.84
0.44
110.00%
HK:1696
Sisram Medical Ltd.
2.85
-1.16
-28.93%
HK:1763
China Isotope & Radiation Corp.
17.97
6.41
55.45%
HK:2170
Suzhou Basecare Medical Corp. Ltd. Class H
1.55
-1.31
-45.80%
HK:6118
Austar Lifesciences Ltd.
0.81
0.09
12.50%
Yestar Healthcare Holdings Co Ltd Corporate Events
Yestar Healthcare Sets 2026 AGM to Approve Results and New Share Mandate
Apr 23, 2026
Yestar Healthcare Holdings Company Limited has called its annual general meeting for 29 May 2026 in Shanghai, where shareholders will review the audited consolidated accounts and directors’ and auditors’ reports for the year ended 31 D...
Yestar Healthcare Swings to 2025 Loss as Revenue Falls and One-Off Gains Disappear
Mar 27, 2026
Yestar Healthcare Holdings reported a sharp revenue decline for 2025, with sales from continuing operations falling to RMB1.49 billion from RMB2.41 billion a year earlier, and the group swinging to a net loss of RMB69.2 million from a RMB903.5 mil...
Yestar Healthcare Flags 2025 Loss After One-Off 2024 Debt Gain
Mar 19, 2026
Yestar Healthcare has warned that it expects to swing to a consolidated net loss of at least RMB65 million for the year ended 31 December 2025, compared with a net profit of about RMB903.5 million a year earlier. The company attributes the reversa...
Yestar Healthcare Warns of 2025 Loss After One-Off Debt Gain Fades
Mar 19, 2026
Yestar Healthcare has warned investors that it expects to swing to a consolidated net loss of at least RMB65 million for 2025, compared with a net profit of about RMB903.5 million a year earlier. The shift largely reflects the absence of a one-off...
Yestar Healthcare Sets March 2026 Board Meeting to Review 2025 Results and Dividend
Mar 16, 2026
Yestar Healthcare Holdings has scheduled a board meeting for 27 March 2026 to consider and approve the annual results for the financial year ended 31 December 2025. The board will also discuss whether to recommend a final dividend, a decision that...
Yestar Healthcare Clarifies Valuation Basis for Advanced Materials Equipment Acquisition
Mar 13, 2026
Yestar Healthcare Holdings has issued a supplemental announcement detailing the valuation basis for its recently disclosed acquisitions of production equipment for advanced materials manufacturing. The company engaged independent valuer Beijing Yi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.